Jin Peipei, Li Hong, Xie Mingran, Tang Jie, Zou Siming, Wang Ruiting, Yu Bin, Chen Tao, Zhang Ju
Department of Clinical Laboratory, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, China.
Front Oncol. 2024 Oct 30;14:1474015. doi: 10.3389/fonc.2024.1474015. eCollection 2024.
We focus on utilizing the Labyrinth system for the detection of circulating tumor cells (CTCs) in patients with lung nodules. Our aim is to evaluate CTCs isolated through the Labyrinth system as a biomarker for early-stage lung cancer (LC) detection.
167 patients with low dose computed tomography (LDCT) diagnostic results for lung nodules and 31 healthy volunteers (HV) were enrolled. Blood samples were processed for CTC detection. LDCT positive (LDCT+) patients underwent surgery and were categorized into those with LC and those with benign lung diseases (BLD) based on their biopsy results. BLD Patients, LDCT negative (LDCT-) patients and HV served as controls. The correlation of CTC counts with LC, BLD, LDCT- and HV was investigated. Receiver operating characteristic (ROC) curves were used to assess the Labyrinth system's diagnostic potential for early-stage LC.
Median CTC counts for LC, BLD, LDCT- and HV were 2.7 CTC/mL, 0.6 CTC/mL, 0.4 CTC/mL, 0 CTC/mL, respectively. Statistical analysis indicated CTC counts could distinguish LC from BLD, LDCT- and HV (p-Values < 0.001). Using a cut-off of 1 CTC/mL, the study showed 84.4% sensitivity and 82.4% specificity for LDCT+ patients. Specificity increased to 85.9% for patients with lung nodules and 88.2% for all participants. In conclusion, CTCs detected by the Labyrinth system can serve as a biomarker for early-stage LC detection for patients with lung nodules.
CTCs identified by the Labyrinth system are a promising biomarker for early-stage LC detection in clinical practice.
我们专注于利用迷宫系统检测肺结节患者的循环肿瘤细胞（CTC）。我们的目的是评估通过迷宫系统分离的CTC作为早期肺癌（LC）检测生物标志物的价值。
纳入167例有肺结节低剂量计算机断层扫描（LDCT）诊断结果的患者和31名健康志愿者（HV）。对血样进行处理以检测CTC。LDCT阳性（LDCT+）患者接受手术，并根据活检结果分为LC患者和良性肺部疾病（BLD）患者。BLD患者、LDCT阴性（LDCT-）患者和HV作为对照。研究了CTC计数与LC、BLD、LDCT-和HV之间的相关性。采用受试者工作特征（ROC）曲线评估迷宫系统对早期LC的诊断潜力。
LC、BLD、LDCT-和HV的CTC计数中位数分别为2.7个CTC/mL、0.6个CTC/mL、0.4个CTC/mL、0个CTC/mL。统计分析表明，CTC计数可将LC与BLD、LDCT-和HV区分开来（p值<0.001）。以1个CTC/mL为临界值，该研究显示LDCT+患者的敏感性为84.4%，特异性为82.4%。肺结节患者的特异性增至85.9%，所有参与者的特异性为88.2%。总之，迷宫系统检测到的CTC可作为肺结节患者早期LC检测的生物标志物。
迷宫系统识别的CTC是临床实践中早期LC检测有前景的生物标志物。
